Reviewing Biomerica (NASDAQ:BMRA) & XORTX Therapeutics (NASDAQ:XRTX)

XORTX Therapeutics (NASDAQ:XRTX) and Biomerica (NASDAQ:BMRA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.

Analyst Ratings

This is a summary of current recommendations and price targets for XORTX Therapeutics and Biomerica, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XORTX Therapeutics	1	0	0	0	1.00
Biomerica	1	0	0	0	1.00

Biomerica has a consensus target price of $9.00, suggesting a potential upside of 448.15%. Given Biomerica’s higher possible upside, analysts clearly believe Biomerica is more favorable than XORTX Therapeutics.

Institutional and Insider Ownership

0.2% of XORTX Therapeutics shares are held by institutional investors. Comparatively, 22.3% of Biomerica shares are held by institutional investors. 6.9% of XORTX Therapeutics shares are held by company insiders. Comparatively, 18.0% of Biomerica shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares XORTX Therapeutics and Biomerica”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XORTX Therapeutics	N/A	N/A	-$2.66 million	($2.63)	-0.78
Biomerica	$5.31 million	0.96	-$4.97 million	($0.89)	-1.84

XORTX Therapeutics has higher earnings, but lower revenue than Biomerica. Biomerica is trading at a lower price-to-earnings ratio than XORTX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

XORTX Therapeutics has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500. Comparatively, Biomerica has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500.

Profitability

This table compares XORTX Therapeutics and Biomerica’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
XORTX Therapeutics	N/A	-150.01%	-106.53%
Biomerica	-96.49%	-98.14%	-70.42%

Summary

Biomerica beats XORTX Therapeutics on 7 of the 11 factors compared between the two stocks.

About XORTX Therapeutics

Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers. Its product and solution portfolio for the enterprise data storage industry includes storage enclosures, integrated application platforms and high performance computing (HPC) data storage solutions. In April 2014, Seagate Technology PLC completed the acquisition of Xyratex Ltd.

About Biomerica

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.